The average sentiment for articles published by this News Source are below.

Anger: Red
Disgust: Olive
Fear: Green
Joy: Gold
Sadness: Blue
View Post

Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

In Uncategorized by Astel LasLeave a Comment

Tech News Keywords: ,

2017 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Na... Read More
View Post

Astellas, the Institute of Medical Science of the University of Tokyo, Chiba University, and Asahi Kogyosha Enter into Collaborative Research Agreement on Rice-based Oral Vaccine “MucoRice”

In Business, Education, Legal, Science & Nature by Astel LasLeave a Comment

Tech News Keywords: , , ,

Tokyo, December 6, 2017 - Astellas Pharma Inc. (Tokyo, President and CEO: Yoshihiko Hatanaka, “Astellas” ), the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”), Chiba University (Chiba, President: Takeshi Tokuhisa, “Chiba University”), and ASAHI KOGYOSHA CO.,LTD. (Tokyo, CEO: Yasutomo Takasu, “Asahi Kogyosha”) today announced that they have signed a collaborative research agreement aiming at the practical application of the rice-based oral vaccine “MucoRice-CTB” (“MucoRice”). This research program has been designated as a project under Cyclic Innovation for Clinical Empowerment (CiCLE)1 and will be supported by the Japan Agency for Medical Research and De... Read More
View Post

Astellas Submits a New Drug Application for Gonax® 12-Week Extended-Release Formulation for Treatment of Prostate Cancer in Japan (pdf 249KB)

In Uncategorized by Astel LasLeave a Comment

Tech News Keywords: ,

2017 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Na... Read More
View Post

MSD and Astellas conclude co-promotion agreement in Japan for type 2 diabetes combination drug

In Business, Emerging Technology, Government, Healthcare by Astel LasLeave a Comment

Tech News Keywords: , , ,

2017 News Releases MSD and Astellas conclude co-promotion agreement in Japan for type 2 diabetes combination drug November 28, 2017 Tokyo, November 28, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that they have concluded a co-promotion agreement (“the Agreement”) for a combination drug of the DPP-4 inhibitor sitagliptin phosphate hydrate (brand name: JANUVIA® Tablets) and the SGLT2 inhibitor ipragliflozin L-Proline (brand name: Suglat® Tablets) for the treatment of type-2 diabetes in Japan (MSD has subm... Read More
View Post

Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer (pdf 284KB)

In Uncategorized by Astel LasLeave a Comment

Tech News Keywords: , ,

2017 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Naviga... Read More
View Post

Astellas Reports First Half FY2017 Financial Results, Revises Fiscal Year Outlook (pdf 432KB)

In Uncategorized by Astel LasLeave a Comment

Tech News Keywords: ,

2017 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Na... Read More
View Post

Astellas Enters into a Screening Collaboration Agreement with MMV to Discover Antimalarial Drugs

In Business, Education, Government, Healthcare by Astel LasLeave a Comment

Tech News Keywords: , , , , ,

Tokyo, October 30, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has entered into a screening collaboration agreement with Medicines for Malaria Venture (“MMV”), a leading product development partnership (PDP) in the field of antimalarial drug research, development and delivery. This collaboration will be funded by the Global Health Innovative Technology Fund1 (“GHIT Fund”) and MMV. Under this agreement, Astellas will provide its library of tens of thousands of compounds, and MMV will work with Prof. Vicky Avery at Griffiths University in Brisbane to screen the library for compounds that demonstrate the potential to become new antimalarial drugs.... Read More
View Post

Extension of Agreement Pertaining to Sale of Telmisartan (Micardis® family)

In Business by Astel LasLeave a Comment

Tech News Keywords: , , ,

2017 News Releases Extension of Agreement Pertaining to Sale of Telmisartan (Micardis® family) October 30, 2017 Tokyo, October 30, 2017 – Nippon Boehringer Ingelheim Co., Ltd. (President and Representative Director: Yoshiaki Aono, “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) announced today that they have agreed to extend the agreement pertaining to the sales of telmisartan (Micardis® family) in Japan to March 31, 2020. The co-promotion agreement will run to March 31, 2018, with no change. The Micardis® family includes “M... Read More
View Post

Astellas Enters into a New Collaborative Research Agreement with TB Alliance to Discover Anti- tuberculosis Drugs

In Business, Healthcare by Astel LasLeave a Comment

Tech News Keywords: , , , ,

Tokyo, October 18, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has entered into a new collaborative research agreement with TB Alliance, a non-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB), for the exploration of new drugs against TB. This research program will be funded by the Global Health Innovative Technology Fund1 (“GHIT Fund”). Under this agreement, Astellas will provide its original library of tens of thousands of compounds, and TB Alliance will be in charge of screening for the discovery of hit compounds to be used in the research and development of new TB drugs. TB is a di... Read More
View Post

U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia (pdf106KB)

In Government, Security by Astel LasLeave a Comment

Tech News Keywords:

2017 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Na... Read More
View Post

Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer (pdf 203KB)

In Uncategorized by Astel LasLeave a Comment

Tech News Keywords: , ,

2017 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Na... Read More
View Post

Astellas and TOA EIYO Announce Co-promotion Agreement for Kiklin® Capsules 250mg and Kiklin® Granules 86.2%

In by Astel LasLeave a Comment

Tech News Keywords: , ,

2017 News Releases Astellas and TOA EIYO Announce Co-promotion Agreement for Kiklin® Capsules 250mg and Kiklin® Granules 86.2% October 2, 2017 Astellas Pharm Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and TOA EIYO LTD. (President: Atsuo Takahashi, “TOA EIYO”) announced that the companies have entered into a co-promotion agreement of Astellas’ products for the treatment of hyperphosphatemia, Kiklin® Capsules 250mg (generic name: Bixalomer, “Kiklin® Capsules”) and Kiklin® Glanules 86.2% (”Kiklin® Granules”), in Japan, starting ... Read More
View Post

Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of “Linaclotide” for Patients with Chronic Constipation in Japan

In Business, Legal by Astel Las

Tech News Keywords: , , , ,

Tokyo, September 11, 2017  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has submitted a supplemental new drug application for marketing approval of the guanylate cyclase-C receptor agonist “linaclotide (generic name) (brand name: Linzess® Tablets 0.25 mg)” for the additional indication of chronic constipation (other than constipation associated with organic disorders*1) (“chronic constipation”). Linaclotide is a guanylate cyclase-C receptor agonist that was introduced from Ironwood Pharmaceuticals, Inc. (“Ironwood”) and has been developed and commercialized by Astellas in Japan. It was approved with the brand name of Linzess... Read More
View Post

Repatha@ Receives Approval for New 420mg Single-Dose Delivery Option in Japan

In Business, Education, Government, Healthcare by Astel Las

Tech News Keywords: , , , , , , ,

2017 News Releases Repatha@ Receives Approval for New 420mg Single-Dose Delivery Option in Japan August 30, 2017 TOKYO (August 30, 2017) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that Amgen Astellas received a marketing approval of Repatha® SC Injection 420 mg Auto mini doser (AMD), an additional dosage formulation of Repatha®, a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin... Read More
View Post

First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplant in Patients with FLT3 Mutation-positive Acute Myeloid Leukemia

In Business, Education, Emerging Technology, Healthcare, Legal by Astel Las

Tech News Keywords: , , , , ,

TOKYO – August 22, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the first patient was dosed in the registrational Phase 3 MORPHO trial of gilteritinib, the fourth Phase 3 trial underway in the gilteritinib clinical development program. The MORPHO trial is a randomized, double-blind, placebo-controlled, multi-center trial that compares gilteritinib to placebo as maintenance therapy over a period of two years following hematopoietic stem cell transplant (HCT) in patients with FLT3 internal tandem duplication (ITD) mutation-positive (FLT3/ITD+) acute myeloid leukemia (AML) and in remission after induction therapy. The primary endpoint is relapse-free... Read More
View Post

LTL Pharma Succeeds Marketing Approval for “Nivadil® Tablets”, “Solantal® Tablets” and “Lowgan® Tablets”, and isTransferred Distribution Rights in Japan

In Business by Astel Las

Tech News Keywords: , , ,

2017 News Releases LTL Pharma Succeeds Marketing Approval for "Nivadil® Tablets", "Solantal® Tablets" and "Lowgan® Tablets", and isTransferred Distribution Rights in Japan August 1, 2017 Tokyo (Japan), August 1, 2017 –LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that from October 1, 2017, LTL Pharma will succeed the marketing approval in Japan from Astellas, for “Nivadil® tablets 2mg, 4mg” (hypertension treatm... Read More
View Post

Astellas Submits Application for Approval of fidaxomicin for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan

In Business, Legal by Astel Las

Tech News Keywords: , , , , , , ,

2017 News Releases Astellas Submits Application for Approval of fidaxomicin for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan July 31, 2017 Tokyo, July 31, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has submitted an application for marketing approval of fidaxomicin (generic name) for the treatment of infectious enteritis (including pseudomembranous colitis1) (susceptible strains: fidaxomicin susceptible Clostridium difficile2). Fidaxomicin is an oral macrocyclic antimicrobial agent3 ... Read More
View Post

Astellas Announces Wind-Down of Agensys Research Operations

In Business, Emerging Technology, Healthcare by Astel Las

Tech News Keywords: , , , , ,

2017 News Releases Astellas Announces Wind-Down of Agensys Research Operations July 27, 2017 TOKYO, July 27, 2017 — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that it is winding down its Agensys research operations in Santa Monica, California, USA, to further refine its oncology strategy by expanding its investment in the research in new technologies and modalities and reducing its focus on Antibody-Drug Conjugate (ADC) research. “Agensys has positively contributed to Astellas’ objective of developing innovative treatments for patients with cancer,... Read More
View Post

U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia

In Business, Government, Healthcare, Legal by Astel Las

Tech News Keywords: , , , ,

2017 News Releases U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia July 21, 2017 TOKYO – July 20, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) granted orphan-drug designation to gilteritinib in patients with acute myeloid leukemia (AML). The Orphan Drug Designation program assigns status to drugs and biologics intended for the safe and effective treatment, diagnosis or prevention of diseases or disorders that affect fewer than 20... Read More
View Post

Astellas Supports the Northern Kyushu Heavy Rain Relief Efforts

In Business by Astel Las

Tech News Keywords: , ,

2017 News Releases Astellas Supports the Northern Kyushu Heavy Rain Relief Efforts July 13, 2017 Tokyo, July 13, 2017– Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) would like to express our deepest sympathy to the victims of the heavy rain hit to Northern Kyushu area in July 2017. Astellas has pledged donations as follows to support victims and to assist in reconstruction efforts. Contributor:Astellas Pharma Inc. Donation to:Japanese Red Cross Society Amount: JPY3,000,000 Astellas hopes for the earliest possible recovery in the affected areas. ###... Read More
View Post

Maruho Succeeds Marketing Approval for Anti-Atopic Dermatitis Agent “Protopic® Ointment” in Japan

In Business, Legal by Astel Las

Tech News Keywords: , , ,

2017 News Releases Maruho Succeeds Marketing Approval for Anti-Atopic Dermatitis Agent "Protopic® Ointment" in Japan July 7, 2017 Osaka and Tokyo (Japan), July 7, 2017 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo, President and CEO: Yoshihiko Hatanaka) announce that from October 1, 2017, Maruho will succeed the marketing approval in Japan from Astellas, for anti-atopic dermatitis agent Protopic® Ointment 0.1% and Protopic® Ointment 0.03% for Pediatric (INN: tacrolimus hydrate, hereinafter refe... Read More
View Post

Astellas Named to FTSE4Good Sustainability Index for the Sixth Consecutive Year

In Business, Science & Nature by Astel Las

Tech News Keywords: , , ,

2017 News Releases Astellas Named to FTSE4Good Sustainability Index for the Sixth Consecutive Year July 5, 2017 Tokyo, July 5, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the sixth consecutive year to be included in the FTSE4Good Index Series, one of the world’s premier indices for socially responsible investment. Managed by FTSE Russell1, the FTSE4Good Index Series serves as a major criterion for investors around the world in assessing social responsibility activities by the companies, when making investment decisions. FTSE Russell ... Read More
View Post

Astellas Submits Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

In Business by Astel Las

Tech News Keywords: , ,

2017 News Releases Astellas Submits Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder June 30, 2017 Tokyo, June 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of mirabegron in combination with solifenacin succinate 5 mg for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. In the... Read More
View Post

The Astellas Oncology C3 Prize Competition Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants (pdf 352KB)

In Uncategorized by Astel Las

Tech News Keywords: , ,

2017 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Na... Read More
View Post

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer (pdf 446)

In Uncategorized by Astel Las

Tech News Keywords: ,

2017 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Naviga... Read More
View Post

Kyoto University and Astellas Inaugurate “Alliance Station” with Aim of Realizing Advanced Medical Treatments

In Business, Education, Legal by Astel Las

Tech News Keywords: , , ,

2017 News Releases Kyoto University and Astellas Inaugurate "Alliance Station" with Aim of Realizing Advanced Medical Treatments June 5, 2017 Kyoto and Tokyo, June 5, 2017  - Kyoto University (President: Juichi Yamagiwa) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the inauguration of Alliance Station (A-Station), a new open innovation scheme at Kyoto University, and the establishment of Alliance Laboratory for Advanced Medical Research as a framework for the  implementation of its activities in Graduate School of Medicine Kyoto University. There are still many unmet medical nee... Read More
View Post

Astellas Announces Commitments to GHIT Fund Replenishment

In Business, Education, Finance, Government, Healthcare, Science & Nature by Astel Las

Tech News Keywords: , , , , , , , , ,

Tokyo, June 1, 2017 – Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, ”Astellas”) today announced that it has committed to supporting the Global Health Innovative Technology Fund (GHIT Fund) for the next 5 years (FY2018 to FY2022) together with a cross-sector group1 of funding partners. A total amount of commitment to the GHIT Fund replenishment is estimated to be over US$ 200 million. The GHIT Fund launched in 2013 to leverage Japanese expertise and capability for life-saving health innovations, including drugs, vaccines and diagnostics, to combat HIV/AIDS, tuberculosis, malaria, neglected tropical diseases (NTDs)2 prevalent in the developing world. A public interest corp... Read More
View Post

ACTION ON FISTULA TO TRANSFORM 4,500 LIVES BY 2020

In Business, Government, Healthcare by Astel Las

Tech News Keywords: , , , , , , , , ,

Tokyo, May 23, 2017 – Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) on International Day to End Obstetric Fistula, Astellas pledges its support to the Fistula Foundation as the second phase of Action on Fistula launches with an ambitious target to treat 4,500 women with obstetric fistula in Kenya by 2020. Action on Fistula, supported by a grant from an affiliate of Astellas Pharma Inc., Astellas Pharma Europe Ltd. (with Astellas Pharma Inc. correctively referred to as "Astellas"), is a programme set up by the Fistula Foundation in 2014 to transform the lives of more than 1,200 women in Kenya living with fistula: an injury caused by prolonged obstructed labour, lea... Read More
View Post

MSD submits application for approval of type-2 diabetes drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor

In Business, Government by Astel Las

Tech News Keywords: , , ,

2017 News Releases MSD submits application for approval of type-2 diabetes drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor May 19, 2017 Tokyo, May 19, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that MSD has submitted an application for marketing approval of a combination drug of the DPP-4 inhibitor sitagliptin phosphate hydrate (brand name: JANUVIA® Tablets) and the SGLT2 inhibitor ipragliflozin L-Proline (brand name: Suglat® Tablets) for the treatment of type-2 diabetes in Japan.... Read More
View Post

Astellas Announces Oncology Portfolio Updates

In Business, Events, Finance, Government, Healthcare, Legal by Astel Las

Tech News Keywords: , , , , , , ,

TOKYO – May 17, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today an update regarding the Company’s diverse oncology portfolio, including the acceptance of a wide selection of abstracts across a broad range of cancers for oral or poster presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago. Astellas is presenting a record number of abstracts at ASCO, including data for gilteritinib in acute myeloid leukemia, enfortumab vedotin in urothelial cancer, and IMAB362 from the recently acquired Ganymed. A number of XTANDI® (enzalutamide) abstracts accepted for presentation also speak to the c... Read More
View Post

Astellas Completes Acquisition of Ogeda SA

In Business, Government by Astel Las

Tech News Keywords: , , ,

2017 News Releases Astellas Completes Acquisition of Ogeda SA May 17, 2017 Tokyo, May 17, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has completed the acquisition of Ogeda SA (formerly named Euroscreen SA, “Ogeda”), a drug discovery company located in Gosselies, Belgium, and Ogeda has become a wholly owned subsidiary of Astellas as of CET May 17, 2017. Under the share purchase agreement executed between Astellas and Ogeda shareholders, Astellas paid EUR 500 million to acquire 100% of the equity in Ogeda. In addition, Ogeda shareholders will become eligi... Read More
View Post

The Institute of Medical Science, the University of Tokyo, and Astellas Enter into an Agreement for Expansion of the Scope of Collaborative Research Utilizing Rice-Based Oral Vaccine”MucoRice” Technology

In Business, Education, Science & Nature by Astel Las

Tech News Keywords: , , ,

2017 News Releases The Institute of Medical Science, the University of Tokyo, and Astellas Enter into an Agreement for Expansion of the Scope of Collaborative Research Utilizing Rice-Based Oral Vaccine"MucoRice" Technology May 11, 2017 Tokyo, May 11, 2016 - the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that they have signed an agreement for expansion of the scope of collaborative research utilizing the rice-based oral vaccine “MucoRice” (“MucoRice”) to viral gastroen... Read More
View Post

Astellas Announces Decision to Discontinue ASP8273 Treatment and Close Randomization for Clinical Study Protocol 8273-CL-0302

In Business, Healthcare, Legal by Astel Las

Tech News Keywords: , , , , ,

2017 News Releases Astellas Announces Decision to Discontinue ASP8273 Treatment and Close Randomization for Clinical Study Protocol 8273-CL-0302 May 11, 2017 Tokyo, May 11, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the discontinuation of ASP8273 treatment arm in the the late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus erlotinib/gefitinib for the 1st line treatment metastatic or advanced unresectable non-small cell lung cancer (NSCLC) harboring sensitizing epidermal growth factor receptor (EGFR) mutation. Following a recommendation by the trial'... Read More
View Post

Transfer of 16 Long-Listed Products in Japan to LTL Pharma: Closing of Asset Purchase Agreement

In Business by Astel Las

Tech News Keywords: , , ,

2017 News Releases Transfer of 16 Long-Listed Products in Japan to LTL Pharma: Closing of Asset Purchase Agreement April 28, 2017 Tokyo, April 28, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that Astellas and LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) confirmed the relevant closing conditions are met on April 28, 2017 to allow the transfer of the assets related to Astellas’ 16 long-listed products (the “Products”) in Japan to LTL Pharma. On March 28, 2017, Astellas and... Read More
View Post

Astellas Announces Cancellation of Treasury Shares

In Business by Astel Las

Tech News Keywords: , ,

2017 News Releases Astellas Announces Cancellation of Treasury Shares April 27, 2017 Tokyo, Japan, April 27, 2017 – Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted that the Company will cancel its treasury shares, pursuant to Article 178 of the Companies Act. Particulars 1.    Class of shares to be cancelled      Common stock of the Company 2.    Number of shares to be cancelled  85 million shares                   ... Read More
View Post

Launch of LINZESS® Tablets 0.25mg in Japan

In Business, Government, Legal by Astel Las

Tech News Keywords: , , ,

Tokyo, March 22, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it launched a guanylate cyclase-C (GC-C) receptor agonist, LINZESS® Tablets (generic name: linaclotide, “LINZESS®”) for irritable bowel syndrome with constipation1) (“IBS-C”) in Japan today.   IBS-C is a functional but not organic disorder which is characterized by abdominal pain and/or discomfort along with abnormal defecation. These gastrointestinal symptoms persist for a long period with frequent remissions and exacerbations. LINZESS® locally binds to the GC-C r... Read More
View Post

Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease

In Business, Events, Healthcare by Astel Las

Tech News Keywords: , , , , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article CAMBRIDGE, Mass. and TOKYO, February 28, 2017 -- Affinivax, Inc. ("Affinivax") and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae (pneumococcus).  The partnership will utilize Affinivax’s proprietary vaccine technology platform – Multiple Antigen Presenting System (MAPS) – to advance a novel MAPS vaccine targeted to prevent and reduce the spread of pneumococcal disease.... Read More
View Post

Kyowa and Astellas enter into an Agreement for Exclusive Distribution and Promotion of Extended-Release Tablets of Quetiapine Fumarate in Japan

In Business, Healthcare by Astel Las

Tech News Keywords: , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2017 News Releases Kyowa and Astellas enter into an Agreement for Exclusive Distribution and Promotion of Extended-Release Tablets of Quetiapine Fumarate in Japan February 27, 2017 Kyowa Pharmaceutical Industry Co., Ltd. (Head office: Yodogawa-ku, Osaka City, President and Representative Director: Ray Tsunoda, hereinafter called “Kyowa”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today ann... Read More
View Post

Joint Storage and Transportation of Pharmaceuticals in Hokkaido by Astellas, Takeda, Teva Takeda Pharma and Teva Takeda Yakuhin – Further ensure stable supplies of pharmaceuticals –

In Business, Healthcare, Science & Nature, Security by Astel Las

Tech News Keywords: , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2017 News Releases Joint Storage and Transportation of Pharmaceuticals in Hokkaido by Astellas, Takeda, Teva Takeda Pharma and Teva Takeda Yakuhin - Further ensure stable supplies of pharmaceuticals - February 23, 2017 Tokyo, February 23, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that Astellas, Takeda Pharmaceutical Company Limited (President and CEO: Christophe Weber, “Takeda”), ... Read More
View Post

Astellas Announces Participation in Access Accelerated – Builds on Company Commitment to improve Access to Health –

In Business, Events, Finance, Government, Healthcare by Astel Las

Tech News Keywords: , , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article Tokyo, January 18, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced its participation in Access Accelerated, a global, multi-stakeholder initiative to advance access to non-communicable disease (NCD) prevention, diagnostics and treatment in low-income and lower-middle income countries. Together with 21 other leading pharmaceutical companies and in collaboration with the World Bank Group and the Union for International Cancer Control (UICC), Astellas will work towards the United Nations Sus... Read More
View Post

Astellas Launches Second Phase of Global Campaign on CNN

In Business, Government, Healthcare, Science & Nature by Astel Las

Tech News Keywords: , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2017 News Releases Astellas Launches Second Phase of Global Campaign on CNN January 12, 2017 Tokyo, January 12, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announces that it will launch the second phase of the ongoing campaign with CNN. Following the initial phase on CNN US and HLN which launched in October 2016, the second phase will begin on January 12, 2017 and run until the end of March 2017 ... Read More
View Post

Astellas Terminates Agreement with UMN Pharma for Cell Culture Based Influenza Vaccine Programs

In Business, Healthcare by Astel Las

Tech News Keywords: , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2017 News Releases Astellas Terminates Agreement with UMN Pharma for Cell Culture Based Influenza Vaccine Programs January 10, 2017 Tokyo, January 10, 2017 - Astellas Pharma Inc. (TSE:4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) announced that it exercised its right to terminate the agreement executed as of September 21, 2010 between Astellas and UMN Pharma Inc. (TSE:4585, Chairman & CEO: Tatsuyoshi Hirano, “UMN Pharma... Read More
View Post
Number of Items Identified: 4
Item #Item NameScoreItem Classification
1clean room0.975
2room0.975
3ultramarine color0.891
4blue color0.775

Notice of Completion of Acquisition of Own Shares

In Business, Healthcare by Astel Las

Tech News Keywords: , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article Tokyo, December 26, 2016 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that it completed acquisition of its own shares, which was resolved by its Board of Directors on October 28, 2016, pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act. Particulars 1. Class of shares acquired:Common stock of the Company 2. Total number of shares acquired:30,000,000 shares 3. Aggregate amount of acquisition cost:45... Read More
View Post
Number of Items Identified: 7
Item #Item NameScoreItem Classification
1Nobelist0.609person, Nobelist
2person0.843
3Labourite0.603person, Labourite
4charcoal color0.841
5jade green color0.615
Number of Faces Detected: 1
Face #Max AgeMin AgeAge CertaintyGenderGender Certainty
1650.670626MALE0.993307

Astellas to Present at J.P. Morgan Healthcare Conference

In Business, Healthcare by Astel Las

Tech News Keywords: , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2016 News Releases Astellas to Present at J.P. Morgan Healthcare Conference December 21, 2016 Tokyo, December 21, 2016 – Astellas Pharma Inc. (the Company) announced that the company's President and CEO Yoshihiko Hatanaka will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 in San Francisco, Calif. The presentation will take place at The... Read More
View Post
Number of Items Identified: 7
Item #Item NameScoreItem Classification
1Nobelist0.609person, Nobelist
2person0.843
3Labourite0.603person, Labourite
4charcoal color0.841
5jade green color0.615
Number of Faces Detected: 1
Face #Max AgeMin AgeAge CertaintyGenderGender Certainty
1650.670626MALE0.993307

Astellas Completes Acquisition of Ganymed Pharmaceuticals

In Business, Government, Healthcare by Astel Las

Tech News Keywords: , , , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2016 News Releases Astellas Completes Acquisition of Ganymed Pharmaceuticals December 21, 2016 Tokyo, December 21, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Ganymed Pharmaceuticals AG (“Ganymed”), a biopharmaceutical company located in Mainz, Germany, and Ganymed has become a wholly owned subsidiary of Astellas as of CET Decem... Read More
View Post

AMGEN ASTELLAS AND ASTELLAS ANNOUNCE SUBMISSION OF APPLICATION FOR INVESTIGATIONAL OSTEOPOROSIS MEDICATION ROMOSOZUMAB IN JAPAN

In Business, Healthcare by Astel Las

Tech News Keywords: , , , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2016 News Releases AMGEN ASTELLAS AND ASTELLAS ANNOUNCE SUBMISSION OF APPLICATION FOR INVESTIGATIONAL OSTEOPOROSIS MEDICATION ROMOSOZUMAB IN JAPAN December 20, 2016 TOKYO (Dec. 20, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Mark Tennyson, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that Amg... Read More
View Post
Number of Items Identified: 6
Item #Item NameScoreItem Classification
1statue0.733figure, sculpture, statue
2sculpture0.888
3figure0.888
4memorial0.659
5alabaster color1

Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions due to Peanut Allergy

In Business, Education, Events, Healthcare, Legal by Astel Las

Tech News Keywords: , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article Tokyo, December 20, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., “Immunomic Therapeutics”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the drug candidate ASP0892 for the mitigation of severe hypersensitivity reactions due to peanut allergy. ASP0892 is a new DNA vaccine program based on the investigational LAMP-Vax platform. A Phase I clinical trial to evaluate the s... Read More
View Post
Number of Items Identified: 9
Item #Item NameScoreItem Classification
1solar thermal system0.78
2system0.78
3solar cell0.764electrical device, solar cell
4electrical device0.851
5device0.851
6shuffleboard0.635sport, shuffleboard
7sport0.636
8steel blue color0.985

Marketing Approval of LINZESS®, Treatment for Irritable Bowel Syndrome with Constipation in Japan – Provides a new therapeutic option for adult patients suffering from irritable bowel syndrome with constipation (IBS-C) –

In Business, Government, Healthcare, Legal by Astel Las

Tech News Keywords: , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article Tokyo, December 19, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it obtained a marketing approval for a guanylate cyclase-C (GC-C) receptor agonist, LINZESS® (generic name: linaclotide Development Code: ASP0456) for irritable bowel syndrome with constipation1) (IBS-C) in adults by the Ministry of Health, Labour and Welfare in Japan today. Astellas expects that obtaining marketing approval of LINZESS... Read More
View Post
Number of Items Identified: 4
Item #Item NameScoreItem Classification
1clean room0.975
2room0.975
3ultramarine color0.891
4blue color0.775

Sysmex, Astellas and Daiichi Sankyo Sign Memorandum of Understanding on the Creation of a Method for Analyzing Circulating Tumor Cells

In Business, Healthcare by Astel Las

Tech News Keywords: , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), Astellas Pharma Inc. (HQ: Tokyo, Japan; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Co., Ltd. (HQ: Tokyo, Japan: President and CEO: Joji Nakayama) have signed a memorandum of understanding to create a method for analyzing circulating tumor cells (CTC)1. Currently, surgically resected tissue (biopsy samples) are applied for the analysis of cells, proteins and genes to provide appropriate therapy for individual cancer... Read More
View Post
Number of Items Identified: 9
Item #Item NameScoreItem Classification
1solar thermal system0.78
2system0.78
3solar cell0.764electrical device, solar cell
4electrical device0.851
5device0.851
6shuffleboard0.635sport, shuffleboard
7sport0.636
8steel blue color0.985

Astellas Announces Transfer of Qutenza to Grünenthal

In Business, Government, Healthcare by Astel Las

Tech News Keywords: , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article TOKYO and CHERTSEY – 12 December, 2016: Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”), today announced that Astellas Pharma Europe Ltd. (“Astellas Pharma Europe”) has entered into a definitive agreement with Grünenthal under which Astellas Pharma Europe will transfer the exclusive rights for Qutenza™ (capsaicin 8% patch) in Europe, Middle East and Africa to Grünenthal. Qutenza is approved by the European Medicines Agency (EMA) for the treatm... Read More
View Post

Astellas Research & Development Meeting Highlights - Turning Innovative Science into Value for Patients -(pdf 237KB)

In Healthcare by Astel Las

Tech News Keywords:

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2016 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page ... Read More
View Post
Number of Items Identified: 7
Item #Item NameScoreItem Classification
1building complex0.651
2medical building0.629
3building0.851
4azure color0.953
5gray color0.797

Astellas Launches Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan

In Business, Events, Government, Healthcare by Astel Las

Tech News Keywords: , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article Tokyo, December 7, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it launched Kiklin® Granules 86.2% (generic name: bixalomer, “Kiklin® Granules”), an additional formulation of Kiklin® Capsules 250 mg (“Kiklin® Capsules”), for the indication of treatment of hyperphosphatemia in patients with chronic kidney disease (“CKD”) in Japan today. Astellas expects to further contribute to hyperphosphatemia treatm... Read More
View Post

Astellas Announces Status of Acquisition of Own Shares (pdf 196KB)

In Healthcare by Astel Las

Tech News Keywords:

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2016 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page ... Read More
View Post

Initiatives to Pursue Operational Excellence

In Business, Healthcare, Science & Nature by Astel Las

Tech News Keywords: , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2016 News Releases Initiatives to Pursue Operational Excellence November 30, 2016 Tokyo, November 30, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) is promoting its strategic goal “Pursuing Operational Excellence” and engaged in ongoing efforts to create organizations and systems that can flexibly respond to rapidly changing environments and realize higher quality and effi... Read More
View Post
Number of Items Identified: 7
Item #Item NameScoreItem Classification
1building complex0.651
2medical building0.629
3building0.851
4azure color0.953
5gray color0.797

Antihypertensive Drug “Micatrio® Combination Tablets”

In Business, Events, Government, Healthcare by Astel Las

Tech News Keywords: , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article Nippon Boehringer Ingelheim Co., Ltd. (Head Office: Tokyo; President and Representative Director: Yoshiaki Aono, hereafter “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Head Office: Tokyo; President and CEO: Yoshihiko Hatanaka, hereafter “Astellas”) announced today that the companies have newly launched “Micatrio® Combination Tablets,” a combination drug of “Micardis® Tablets” (AT1 receptor blocker [ARB]), long-acting calcium channel blocker (CCB) amlodipine besylate and the thiazide diuret... Read More
View Post
Number of Items Identified: 6
Item #Item NameScoreItem Classification
1barricade0.803barrier, barricade
2barrier0.852
3news magazine0.6
4magazine0.664
5lemon yellow color1

GUINNESS WORLD RECORDSTM Title Achieved for Organ Donor Registrations

In Business, Gaming, Government, Healthcare, Mobile Technology by Astel Las

Tech News Keywords: , , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article Astellas, Donate Life America and World Transplant Games Federation Celebrate Achievements for Global Transplant Community at History-making Rugby Match TOKYO and CHICAGO, Ill. – Nov. 9 2016 – Astellas Pharma Inc. (TSE: 4503, collectively with its subsidiaries “Astellas”), Donate Life America and the World Transplant Games Federation today announced that Astellas and Donate Life America registered thousands of new organ donors and tripled the previous GUINNESS WORLD RECORDS™ t... Read More
View Post

Astellas Announces Status of Acquisition of Own Shares (pdf 187KB)

In Healthcare by Astel Las

Tech News Keywords:

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2016 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page ... Read More
View Post
Number of Items Identified: 6
Item #Item NameScoreItem Classification
1barricade0.803barrier, barricade
2barrier0.852
3news magazine0.6
4magazine0.664
5lemon yellow color1

Astellas to Acquire Ganymed Pharmaceuticals -Acquisition Would Expand Astellas' Oncology Pipeline with Antibody in Late-Stage –

In Business, Finance, Government, Healthcare, Legal, Science & Nature by Astel Las

Tech News Keywords: , , , , , , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article Tokyo and Mainz, October 28, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s shareholders have entered into an agreement for Astellas to acquire Ganymed. The transaction would enable Astellas to continue to build upon its leading oncology franchise as a platform for ... Read More
View Post

Astellas Reports First Half FY2016 Financial Results, Revises Fiscal Year Outlook (pdf 430KB)

In Business, Finance by Astel Las

Tech News Keywords: ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2016 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page ... Read More

Astellas Announces Acquisition of Own Shares (pdf 175KB)

In Business by Astel Las

Tech News Keywords:

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article 2016 News Releases | Astellas Pharma Inc. This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page ... Read More
View Post
Number of Items Identified: 6
Item #Item NameScoreItem Classification
1barricade0.803barrier, barricade
2barrier0.852
3news magazine0.6
4magazine0.664
5lemon yellow color1

FDA Approves Supplemental New Drug Application for XTANDI in Advanced Prostate Cancer

In Government, Healthcare, Legal by Astel Las

Tech News Keywords: , , , ,

TOKYO and NEW YORK, Oct. 21, 2016 -- Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XTANDI® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (CRPC) who were treated with enzalutamide compared to patients who were treated with bicalutamide. The TERRAIN study evaluated men with metastatic CRPC and the results from this study were published in the Lan... Read More
View Post

Updated clinical data of enfortumab vedotin (ASG-22ME) and ASG-15ME were presented at the European Society for Medical Oncology (ESMO) Congress.

In Healthcare by Astel Las

Tech News Keywords: , , ,

Astellas Pharma Inc. | Investor Relations This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Navigation end Home > Investor Relations ... Read More
View Post

Annual Report 2016 is now available.

In Business by Astel Las

Tech News Keywords: , ,

Astellas Pharma Inc. | Investor Relations This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Navigation end Home > Investor Relations ... Read More
View Post

Posted Financial Results for 1Q/FY2016

In Finance by Astel Las

Tech News Keywords: , ,

Astellas Pharma Inc. | Investor Relations This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Navigation end Home > Investor Relations ... Read More
View Post

Phase-1 data of ASG-15ME and ASG-22ME were presented at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting

In Healthcare by Astel Las

Tech News Keywords: , , ,

Astellas Pharma Inc. | Investor Relations This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Navigation end Home > Investor Relations ... Read More
View Post

Posted Notification of Convocation of the 11th Term Annual Shareholders Meeting

In Business by Astel Las

Tech News Keywords: , ,

Astellas Pharma Inc. | Investor Relations This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Navigation end Home > Investor Relations ... Read More
View Post

Posted Financial Results for FY2015

In Finance by Astel Las

Tech News Keywords: , ,

Astellas Pharma Inc. | Investor Relations This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Navigation end Home > Investor Relations ... Read More
View Post

Posted Corporate Governance Report

In Business, Legal by Astel Las

Tech News Keywords: , ,

Astellas Pharma Inc. | Investor Relations This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Navigation end Home > Investor Relations ... Read More
View Post

Posted Financial Results for 3Q/FY2015

In Finance by Astel Las

Tech News Keywords: , ,

Astellas Pharma Inc. | Investor Relations This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Navigation end Home > Investor Relations ... Read More
View Post

Journal of Clinical Oncology Publishes Results from the STRIVE trial of enzalutamide

In Healthcare by Astel Las

Tech News Keywords: , ,

Astellas Pharma Inc. | Investor Relations This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Navigation end Home > Investor Relations ... Read More
View Post

Lancet Oncology Publishes Results from the Phase 2 TERRAIN Trial of enzalutamide.

In Healthcare by Astel Las

Tech News Keywords: , ,

Astellas Pharma Inc. | Investor Relations This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Navigation end Home > Investor Relations ... Read More
View Post

Posted Presentation Slides for Conference Hosted by J.P. Morgan

In Events by Astel Las

Tech News Keywords: , ,

Astellas Pharma Inc. | Investor Relations This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Navigation end Home > Investor Relations ... Read More
View Post

NICE Final Appraisal Determination (FAD) recommends use of prostate cancer treatment XTANDI (enzalutamide) prior to chemotherapy

In Healthcare by Astel Las

Tech News Keywords: , ,

Astellas Pharma Inc. | Investor Relations This web site requires JavaScript enabled in your browser. You have to enable JavaScript to change font-size and listen selected texts by the voice. To scroll text in this page Global Navigation end Home > Investor Relations ... Read More
View Post

Astellas Launches Global Campaign in Collaboration with CNN as Part of Global Corporate Brand Activity -Sponsors CNN Heroes Starting October 20 –

In Business, Government, Healthcare, Mobile Technology, Science & Nature by Astel Las

Tech News Keywords: , , , ,

Tokyo, October 20, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announces that it will launch the newest element in its global corporate brand campaign which is conducting in collaboration with CNN. The first phase of the new campaign will begin on October 20, 2016 on CNN US and HLN and run through March 2017 on CNN International. In the global corporate brand campaign, as one of the sponsors of “CNN Heroes” which is broadcasted on CNN US and HLN, Astellas will expand its brand campaign with a TV commercial and digital activities on relevant websites and social media platforms. The company’s new commercial features three Astellas employees in locations around the world an... Read More